FDA Chief Proposes Major Shift to Expand Over-the-Counter Drug Access by 2026

FDA Commissioner Marty Makary has announced a significant policy shift aimed at reclassifying a wide range of prescription medications as over-the-counter (OTC) products. Speaking on the new directive, Makary emphasized that most drugs should be accessible without a prescription unless they are proven unsafe or carry a high risk of addiction. The agency is currently evaluating specific categories for this transition, including nausea medications and vaginal estrogen treatments. This regulatory overhaul is expected to be implemented within the 2026 calendar year, marking a rapid change in U.S. healthcare policy. While the move could pressure profit margins for major pharmaceutical companies like PFE and JNJ, it is viewed as a potential catalyst for retail pharmacies such as CVS and WBA due to increased consumer volume. The initiative aims to reduce consumer costs and administrative burdens by streamlining access to essential healthcare products.